P Piccini

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi request reprint Endogenous dopamine release after pharmacological challenges in Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:647-53. 2003
  2. ncbi request reprint Dopamine transporter: basic aspects and neuroimaging
    Paola P Piccini
    MRC Clinical Sciences Centre, and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 18:S3-8. 2003
  3. ncbi request reprint Functional brain imaging in the differential diagnosis of Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Lancet Neurol 3:284-90. 2004
  4. ncbi request reprint Neurodegenerative movement disorders: the contribution of functional imaging
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Curr Opin Neurol 17:459-66. 2004
  5. ncbi request reprint New developments of brain imaging for Parkinson's disease and related disorders
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 21:2035-41. 2006
  6. ncbi request reprint Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography
    P Piccini
    MRC Clinical Science Center, Imperial College School of Medicine, Hammersmith Hospital, DuCane Road, W12 ONN London, England
    Arch Neurol 58:1846-51. 2001
  7. pmc The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
    P Piccini
    Department of Neurology, Imperial College, School of Medicine, Hammersmith Hospital, London, UK
    J Neurol Neurosurg Psychiatry 68:589-94. 2000
  8. ncbi request reprint Dyskinesias after transplantation in Parkinson's disease
    Paola Piccini
    PET Neurology Group, MRC Clinical Sciences Centre and Division of Neurosciences, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK
    Lancet Neurol 1:472. 2002
  9. ncbi request reprint Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
    P Piccini
    MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Nat Neurosci 2:1137-40. 1999
  10. doi request reprint Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease
    I Reuter
    Academic Department of Neuroscience, Kings College Hospital, London, UK
    J Neurol Neurosurg Psychiatry 79:948-51. 2008

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Endogenous dopamine release after pharmacological challenges in Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:647-53. 2003
    ..Our data also show that the capacity to release normal DA levels in prefrontal areas after a pharmacological challenge is preserved in severe stages of the disease...
  2. ncbi request reprint Dopamine transporter: basic aspects and neuroimaging
    Paola P Piccini
    MRC Clinical Sciences Centre, and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 18:S3-8. 2003
    ....
  3. ncbi request reprint Functional brain imaging in the differential diagnosis of Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Lancet Neurol 3:284-90. 2004
    ..Functional neuroimaging holds the promise of improved diagnosis and allows assessment in early disease. In this review, the use of PET and single photon emission CT in the differential diagnosis of IPD are discussed...
  4. ncbi request reprint Neurodegenerative movement disorders: the contribution of functional imaging
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Curr Opin Neurol 17:459-66. 2004
    ..This review discusses recent findings in this field, with a focus on the detection and characterization of receptor binding and presynaptic dopamine changes in movement disorders...
  5. ncbi request reprint New developments of brain imaging for Parkinson's disease and related disorders
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 21:2035-41. 2006
    ..This review focuses on these recent advances in neuroimaging technology and their use for the diagnosis and assessment of PD and other parkinsonian disorders...
  6. ncbi request reprint Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography
    P Piccini
    MRC Clinical Science Center, Imperial College School of Medicine, Hammersmith Hospital, DuCane Road, W12 ONN London, England
    Arch Neurol 58:1846-51. 2001
    ..The rarity of reports of familial PSP may be attributed in part to an inability to detect subclinical disease in affected relatives who subsequently die before symptoms clinically develop...
  7. pmc The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
    P Piccini
    Department of Neurology, Imperial College, School of Medicine, Hammersmith Hospital, London, UK
    J Neurol Neurosurg Psychiatry 68:589-94. 2000
    ....
  8. ncbi request reprint Dyskinesias after transplantation in Parkinson's disease
    Paola Piccini
    PET Neurology Group, MRC Clinical Sciences Centre and Division of Neurosciences, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK
    Lancet Neurol 1:472. 2002
  9. ncbi request reprint Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
    P Piccini
    MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Nat Neurosci 2:1137-40. 1999
    ..Despite an ongoing disease process, grafted neurons can thus continue for a decade to store and release dopamine and give rise to substantial symptomatic relief...
  10. doi request reprint Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease
    I Reuter
    Academic Department of Neuroscience, Kings College Hospital, London, UK
    J Neurol Neurosurg Psychiatry 79:948-51. 2008
    ..The other patient did not improve clinically or radiologically. Our results indicate that striatal transplantation in HD may be beneficial but further studies are needed to confirm this...
  11. ncbi request reprint Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study
    N Pavese
    MRC Clinical Sciences Centre and Division of Neurosciences, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
    Neurology 67:1612-7. 2006
    ..To evaluate the relationship between clinical improvement and in vivo synaptic dopamine (DA) release after a single oral dose of levodopa (LD) in patients with advanced Parkinson disease (PD)...
  12. ncbi request reprint Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study
    Y F Tai
    MRC Clinical Sciences Centre and Division of Neurosciences, Hammersmith Hospital, Imperial College London, United Kingdom
    J Neural Transm 114:337-40. 2007
    ..This is the first in vivo documentation of cortical dopaminergic deficiency in PSP. Reduced striatal (18)F-dopa uptake in susceptible relatives may predict later clinical disease...
  13. ncbi request reprint Factors affecting the clinical outcome after neural transplantation in Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 128:2977-86. 2005
    ..Finally, our data provide evidence that long-term immunosuppression can be withdrawn without interfering with graft survival or the motor recovery induced by transplantation...
  14. ncbi request reprint Microglial activation in presymptomatic Huntington's disease gene carriers
    Yen F Tai
    MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Brain 130:1759-66. 2007
    ..PK PET may be a useful marker of active subclinical disease and a means of investigating the efficacy of neuroprotection strategies in PGCs...
  15. ncbi request reprint Microglial activation correlates with severity in Huntington disease: a clinical and PET study
    N Pavese
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Neurology 66:1638-43. 2006
    ..In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process...
  16. ncbi request reprint Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study
    Nicola Pavese
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 126:1127-35. 2003
    ..This probably reflects both contributions from other affected brain structures and high variance in these measures...
  17. doi request reprint Hypothalamic involvement in Huntington's disease: an in vivo PET study
    Marios Politis
    Division of Clinical Neurosciences and MRC Clinical Sciences Centre, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK
    Brain 131:2860-9. 2008
    ....
  18. ncbi request reprint Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation
    N L Khan
    MRC Clinical Sciences Centre, and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Neurology 64:134-6. 2005
    ..Four had subtle extrapyramidal signs. Parkin heterozygosity is a risk factor for nigrostriatal dysfunction and in some may contribute to late-onset Parkinson disease...
  19. doi request reprint Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures
    M Politis
    MRC Clinical Sciences Centre and Centre for Neuroscience, Faculty of Medicine, Imperial CollegeLondon, UK
    Neurology 75:1920-7. 2010
    ..Depression associated with Parkinson disease (PD) has a different symptom profile to endogenous depression. The etiology of depression in PD remains uncertain though abnormal serotonergic neurotransmission could play a role...
  20. ncbi request reprint Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study
    Ines K Goerendt
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 126:312-25. 2003
    ..These findings confirm that striatal dopamine release is a component of movement sequencing and show that dopamine release can be detected in early Parkinson's disease during a behavioural manipulation...
  21. ncbi request reprint 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
    Roberto Ceravolo
    MRC Cyclotron Unit, Hammersmith Hospital, Institute of Neurology, London, UK
    Synapse 43:201-7. 2002
    ..0059 +/- 0.0028) in the absence of this drug. These findings are compatible with clinical doses of tolcapone having a significant blocking effect on peripheral and central COMT but not DDC activity in PD...
  22. doi request reprint Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study
    Nicola Pavese
    MRC Clinical Science Centre, Imperial College, London, United Kingdom nicola pavese csc mrc ac uk
    Mov Disord 24:2260-6. 2009
    ..Although subclinical reductions of striatal (18)F-dopa uptake are common in carriers of a single parkin mutation their slow rate of progression suggests that few if any of these will develop clinical parkinsonism...
  23. ncbi request reprint Compulsive drug use linked to sensitized ventral striatal dopamine transmission
    Andrew H Evans
    Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, London, United Kingdom
    Ann Neurol 59:852-8. 2006
    ..We aimed to evaluate levodopa-induced dopamine neurotransmission in the striatum of patients with DDS compared with PD control patients...
  24. ncbi request reprint Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study
    Naheed L Khan
    MRC Clinical Sciences Centre, and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Brain 125:2248-56. 2002
    ..However, the two carriers scanned twice showed no progression over a 7-year period. The slower rate of disease progression in parkin patients may explain the near normal longevity of these patients with young onset parkinsonism...
  25. doi request reprint Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management
    K Wu
    Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK
    Postgrad Med J 85:590-6. 2009
    ..This review aims to summarise the current literature on ICDs, their phenomenology, epidemiology, clinical features, pathophysiology and management...
  26. ncbi request reprint Imaging in Parkinson's disease: the role of monoamines in behavior
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College London, United Kingdom
    Biol Psychiatry 59:908-18. 2006
    ..Novel markers of amyloid plaque load will also help clarify the etiology of dementia in PD...
  27. doi request reprint Neuroprotection and imaging studies in Parkinson's disease
    Nicola Pavese
    Division of Neurosciences and Mental Health and MRC Clinical Sciences Centre, Faculty of Medicine, Hammersmith Hospital, Imperial College, London, UK
    Parkinsonism Relat Disord 15:S33-7. 2009
    ..In this article the value of imaging as a biomarker for testing neuroprotective agents in PD is reviewed...
  28. doi request reprint In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study
    Nicola Pavese
    MRC Clinical Science Centre and Division of Neuroscience and Mental Health, Imperial College, London, UK
    Exp Neurol 222:120-4. 2010
    ..These findings suggest that parkin patients and IPD patients with similar striatal dysfunction have different patterns of monoaminergic involvement, with more widespread dysfunction in IPD...
  29. doi request reprint Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers
    Nicola Pavese
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Neurobiol Dis 37:356-61. 2010
    ..It is an early event in HD pathophysiology and could contribute to the impairment in neuropsychological performance in these patients...
  30. doi request reprint Cognitive deficits and striato-frontal dopamine release in Parkinson's disease
    Nobukatsu Sawamoto
    Division of Neuroscience, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN, UK
    Brain 131:1294-302. 2008
    ..In contrast, mesocortical dopaminergic transmission appears well preserved in early PD patients...
  31. ncbi request reprint Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study
    Naheed L Khan
    Department of Molecular Pathogenesis, Institute of Neurology, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
    Ann Neurol 52:849-53. 2002
    ..The subclinical loss of striatal dopamine storage capacity found in the PARK6 carriers implies that the unidentified gene on the short arm of chromosome 1 exhibits either haploinsufficency or a dominant negative effect...
  32. ncbi request reprint Imaging microglial activation in Huntington's disease
    Yen F Tai
    Division of Neuroscience and Psychological Medicine, Hammersmith Hospital, Imperial College London, UK
    Brain Res Bull 72:148-51. 2007
    ..Further longitudinal studies are needed to fully elucidate this link...
  33. ncbi request reprint Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study
    D J Nicholl
    Department of Neurology, Queen Elizabeth Hospital, Birmingham, UK
    Brain 125:44-57. 2002
    ..These kindreds are distinct from other Parkinsonian kindreds with identified genetic loci (PARK1-4) and provide further evidence for genetic heterogeneity in familial Parkinson's disease...
  34. ncbi request reprint Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6)
    Naheed L Khan
    Department of Molecular Neurosciences, Institute of Neurology, London, United Kingdom
    Mov Disord 20:1115-9. 2005
    ..We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction. Moreover, isolated cases may be confused with multiple system atrophy...
  35. pmc Applications of positron emission tomography (PET) in neurology
    Y F Tai
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    J Neurol Neurosurg Psychiatry 75:669-76. 2004
    ..This article aims to provide an overview of the principles of PET and its applications to clinical neurology...
  36. doi request reprint Positron emission tomography imaging in multiple sclerosis-current status and future applications
    L Kiferle
    Centre for Neuroscience and MRC Clinical Sciences Centre, Division of Experimental Medicine, Hammersmith Hospital, Imperial College London, London, UK
    Eur J Neurol 18:226-31. 2011
    ..The recent development of new radiolabelled ligands provides positron emission tomography (PET) imaging with a role for studying early aspects of the MS pathology...
  37. ncbi request reprint Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data
    Naheed L Khan
    Department of Molecular Neuroscience, Institute of Neurology, London, UK
    Brain 128:2786-96. 2005
    ....
  38. doi request reprint PET image denoising using a synergistic multiresolution analysis of structural (MRI/CT) and functional datasets
    Federico E Turkheimer
    Department of Clinical Neuroscience, Division of Neuroscience and Mental Health, Imperial College, London, United Kingdom
    J Nucl Med 49:657-66. 2008
    ..The method can be naturally extended to other functional imaging modalities (SPECT, functional MRI)...
  39. ncbi request reprint Cardiovascular effects of methamphetamine in Parkinson's disease patients
    Nicola Pavese
    MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College Hammersmith Hospital Campus, London, United Kingdom
    Mov Disord 19:298-303. 2004
    ..These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment...
  40. doi request reprint Parkinson's disease symptoms: the patient's perspective
    Marios Politis
    Department of Clinical Neurosciences, Faculty of Medicine, Hammersmith Hospital, Imperial College, London, United Kingdom
    Mov Disord 25:1646-51. 2010
    ....
  41. ncbi request reprint Ecstasy (MDMA) does not have long-term effects on aggressive interpretative bias: a study comparing current and ex-ecstasy users with polydrug and drug-naive controls
    Rosa Hoshi
    Clinical Psychopharmacology Unit, University College London, London, United Kingdom
    Exp Clin Psychopharmacol 15:351-8. 2007
    ....
  42. ncbi request reprint Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations
    Christoph Scherfler
    MRC Clinical Science Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 21:783-8. 2006
    ..Parkin-positive patients appear to have a greater susceptibility to the exposure to dopaminergic medication than IPD patients, which in turn might be an indirect effect of their genetic mutation...
  43. ncbi request reprint Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism
    Christoph Scherfler
    MRC Clinical Science Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Brain 127:1332-42. 2004
    ..Cortical reductions in D2 binding may contribute to the behavioural problems reported in parkin patients...
  44. ncbi request reprint Plasticity of the nigropallidal pathway in Parkinson's disease
    Alan L Whone
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:206-13. 2003
    ....